The earnings call highlighted strong revenue growth, significant increases in prescriptions and market expansion, and successful clinical trial results. However, the call also noted challenges, such as a slight decline in net income, pharmacy capacity issues affecting revenue, and ongoing patent litigation. Despite these challenges, the overall sentiment leans positive due to promising trial results and strategic expansions.

Company Guidance

In the second quarter of 2025, Corcept Therapeutics reported revenue of $194.4 million, a significant increase from $163.8 million in the same period last year. The company has adjusted its 2025 revenue guidance to a range of $850 million to $900 million. Net income was slightly lower at $35.1 million compared to $35.5 million in the previous year. As of June 30, Corcept had $515 million in cash and investments, reflecting activities such as a $115 million stock repurchase. The endocrinology division saw record growth, with a 49% increase in tablet shipments year-over-year, although fulfillment issues with their pharmacy vendor impacted financial results by approximately $15 million. The company expects these issues to improve with increased pharmacy capacity and the addition of a second pharmacy in the fourth quarter. Corcept is optimistic about future growth, driven by increased awareness and treatment of hypercortisolism, with plans to expand its sales force and anticipate relacorilant's approval. They also forecast relacorilant could achieve $3 billion to $5 billion in annual revenue in the next 3 to 5 years.

Revenue Increase

Revenue for the second quarter of 2025 was $194.4 million, a 18.7% increase compared to $163.8 million in the prior year period.

Tablet Shipment Growth

A 49% increase in tablet shipments compared to the second quarter of the previous year, with a record number of new prescribers and new prescriptions.

Expansion in Endocrinology Division

A significant increase in the sales force from 60 clinical specialists in early 2024 to 145, with plans to reach 175 by year-end.

Catalyst Study Results

The CATALYST study found that 1 in 4 patients with difficult-to-control diabetes have hypercortisolism, leading to higher screening and treatment rates.

ROSELLA Trial Success

The ROSELLA trial met its primary endpoint with a 30% reduction in the risk of disease progression in platinum-resistant ovarian cancer.

NDA Submissions

Two new drug applications in progress for hypercortisolism and platinum-resistant ovarian cancer.

Corcept Therapeutics (CORT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CORT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.17 / -	0.41	―	―	―
Jul 31, 2025	2025 (Q2)	0.19 / 0.29	0.32	-9.38% (-0.03)	―
May 05, 2025	2025 (Q1)	0.14 / 0.17	0.25	-32.00% (-0.08)
Feb 26, 2025	2024 (Q4)	0.43 / 0.26	0.28	-7.14% (-0.02)	―
Oct 30, 2024	2024 (Q3)	0.28 / 0.41	0.28	46.43% (+0.13)	―
Jul 29, 2024	2024 (Q2)	0.23 / 0.32	0.25	28.00% (+0.07)	―
May 01, 2024	2024 (Q1)	0.22 / 0.25	0.14	78.57% (+0.11)	―
Feb 15, 2024	2023 (Q4)	0.26 / 0.28	0.14	100.00% (+0.14)	―
Nov 01, 2023	2023 (Q3)	0.22 / 0.28	0.3	-6.67% (-0.02)	―
Aug 02, 2023	2023 (Q2)	0.15 / 0.25	0.24	4.17% (+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CORT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$67.17	$69.00	+2.72%
May 05, 2025	$73.94	$70.74	-4.33%
Feb 26, 2025	$63.37	$59.85	-5.55%
Oct 30, 2024	$46.89	$48.97	+4.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Corcept Therapeutics Inc. (CORT) report earnings?

Corcept Therapeutics Inc. (CORT) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).

What is Corcept Therapeutics Inc. (CORT) earnings time?

Corcept Therapeutics Inc. (CORT) earnings time is at Oct 29, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CORT EPS forecast?

CORT EPS forecast for the fiscal quarter 2025 (Q3) is 0.17.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing